Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

摘要

Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic + NSCLC based on results from the Phase II global NP28673 ( ) and North American NP28761 ( ) studies.